Janus Henderson Group’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$221M Buy
+1,569,992
New +$224M 0.09% 196
2026
Q1
$305M Buy
2,891,527
+241,546
+9% +$21.4M 0.15% 148
2025
Q4
$231M Buy
2,649,981
+1,549,160
+141% +$127M 0.1% 176
2025
Q3
$73.2M Buy
1,100,821
+653,993
+146% +$37.2M 0.03% 334
2025
Q2
$24.7M Buy
446,828
+425,374
+1,983% +$20.4M 0.01% 529
2025
Q1
$1.05M Hold
21,454
– – ﹤0.01% 1598
2024
Q4
$828K Hold
21,454
– – ﹤0.01% 1783
2024
Q3
$965K Hold
21,454
– – ﹤0.01% 1685
2024
Q2
$743K Sell
21,454
-281
-1% -$8.23K ﹤0.01% 1783
2024
Q1
$628K Buy
21,735
+1
+0% +$27 ﹤0.01% 1897
2023
Q4
$499K Sell
21,734
-41
-0.2% -$717 ﹤0.01% 1986
2023
Q3
$364K Buy
21,775
+20
+0.1% +$388 ﹤0.01% 2095
2023
Q2
$601K Buy
21,755
+4,505
+26% +$113K ﹤0.01% 1875
2023
Q1
$397K Buy
+17,250
New +$290K ﹤0.01% 2144
2022
Q1
– Sell
-8,014
Closed -$274K – 2694
2021
Q4
$274K Buy
+8,014
New +$253K ﹤0.01% 2240

Other funds holding PTGX

Janus Henderson Group's PTGX Position: Q3 2026 in Review

Janus Henderson Group opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 1,569,992 shares worth $221M. The stake represents 0.09% of the portfolio and ranks #196 among its holdings. This is a return to the name: Janus Henderson Group previously reported a position in PTGX as recently as Q1 2026.

Janus Henderson Group first reported a position in PTGX in Q4 2021 and has held it in 15 quarters since. The position peaked at $305M in Q1 2026. 379 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Janus Henderson Group held 1,569,992 shares of Protagonist Therapeutics worth $221M as of Q3 2026.
  • Protagonist Therapeutics was a new Janus Henderson Group position in Q3 2026.
  • Protagonist Therapeutics made up 0.09% of Janus Henderson Group's portfolio in Q3 2026, its #196 holding.
  • Janus Henderson Group first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Janus Henderson Group's Protagonist Therapeutics position peaked at $305M in Q1 2026.
  • 379 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Janus Henderson Group's 13F filing for Q3 2026, filed 16 Nov 2026.